Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug.

ABSTRACT:

Background

COVID-19 disease caused by SARS-CoV-2 is lacking efficient medication although certain medications are used to relief its symptoms.

Objectives

We tested an FDA-approved antiviral medication namely rilpivirine to find a drug against SARS-CoV-2.

Methods

The inhibition of rilpivirine against multiple SARS-CoV-2 therapeutic targets was studied using in silico method. The binding attraction of the protein-ligand complexes were calculated using molecular docking analysis.

Results

Docking rilpivirine with main protease (Mpro), papin like protease (PLpro), sprike protein (Spro), human angiotensin converting enzyme-2 (ACE2), and RNA dependent-RNA polymerase (RdRp) yielded binding energies of -8.07, -8.40, -7.55, -9.11, and -8.69 kcal/mol, respectively. The el

SUBMITTER: Ameen F 

PROVIDER: S-EPMC8294774 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature